US Bioservices selected by TESARO to dispense ZEJULA™ (niraparib)

April 19, 2017


Frisco, Texas – US Bioservices, an independent specialty pharmacy and part of AmerisourceBergen, announced today it has been selected by TESARO, Inc. as a specialty pharmacy partner for ZEJULA (niraparib). The U.S. Food and Drug Administration approved ZEJULA on March 27, 2017, for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy.

“With the addition of ZEJULA, US Bioservices strengthens its offerings for women and oncology,” adds Aaron Sathre, Senior Vice President of Client Growth and Development, US Bioservices. “As an independent specialty pharmacy with a dedicated Oncology Patient Support Team, US Bioservices provides high-touch clinical care that is specific to patient needs, conditions and therapies. Our multidisciplinary teams are organized to develop long-standing, collaborative relationships with oncologists, resulting in more integrated care for patients and caregivers.”

AmerisourceBergen is committed to ensuring treatment reaches those who need it most. Company experts partner with manufacturers to design an integrated commercialization solution around individual products and the unique needs of patients, providing end-to-end support for each step of the product and patient journey.

ZEJULA is only available from select specialty pharmacies, in-office dispensing practices, and hospitals.

Physicians may submit prescriptions to US Bioservices via phone (877.757.0667), fax (888.899.0067), ePrescribe or the MyPathpoint Prescriber Portal.


About AmerisourceBergen